Navigation Links
Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
Date:3/14/2008

HAYWARD, Calif., March 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Gary S. Titus, Kosan's Senior Vice President and Chief Financial Officer, will present at the Cowen and Company 28th Annual Health Care Conference in Boston at the Boston Marriott Copley Place on Wednesday, March 19, 2008 at 8:00 a.m. Eastern Time. A live webcast of the presentation can be accessed through http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=KOSN&item_id=17865 88.

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentation will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Kosan Announces Third Quarter 2007 Financial Results
7. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
8. Kosan Announces February 28, 2008 Conference Call and Webcast
9. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
10. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
11. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... used in spinal surgical procedures, today announced the completion of a significant transaction ... for current and future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), ...
(Date:4/29/2016)... , April 29, 2016 ... by Transparency Market Research "Separation Systems for Commercial ... Growth, Trends, and Forecast 2015 - 2023", the ... at US$ 10,665.5 Mn in 2014 and is ... from 2015 to 2023 to reach US$ 19,227.8 ...
(Date:4/29/2016)... ... 29, 2016 , ... During a two day program for ... company, CereScan’s CEO, John Kelley, joined other Denver business leaders in providing business ... the Denver area business community, shared his top fundamental learnings in building an ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Summit ... (NSCF) to support the development of a patient-specific stem cell therapy for the treatment ... the lab of Dr. Jeanne Loring at The Scripps Research Institute in San Diego, ...
Breaking Biology Technology:
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):